07:18 AM EST, 11/12/2024 (MT Newswires) -- Astrazeneca ( AZN ) said Tuesday it will make a $3.5 billion in capital investment in the United States to expand its research and manufacturing capabilities by the end of 2026.

The investment includes $2 billion to create over 1,000 jobs.

Key projects include a state-of-the-art R&D center in Cambridge, Massachusetts, advanced biologics manufacturing in Maryland, cell therapy facilities on both U.S. coasts, and specialty manufacturing in Texas.

AstraZeneca ( AZN ) said the investment is part of its long-term goal to achieve $80 billion in total revenue by 2030, with the U.S. market contributing 44% of its revenue.

Price: 63.54, Change: -1.25, Percent Change: -1.93